study has revolutionized the concept of the effective treatment of hypertension. 1 The findings showed that aggressive systolic blood pressure (SBP) control to <120 mm Hg was associated with significant reduction of the primary composite outcome of myocardial infarction (MI), other coronary syndromes, stroke, heart failure (HF), or death from cardiovascular (CV) causes in both older men and women and even those 75 years and older. 
| INTRODUCTION
The recently published Systolic Blood Pressure Intervention (SPRINT) study has revolutionized the concept of the effective treatment of hypertension. 1 The findings showed that aggressive systolic blood pressure (SBP) control to <120 mm Hg was associated with significant reduction of the primary composite outcome of myocardial infarction (MI), other coronary syndromes, stroke, heart failure (HF), or death from cardiovascular (CV) causes in both older men and women and even those 75 years and older. 2 These findings have prompted plans to revise the blood pressure (BP) treatment guidelines according to SPRINT. However, aggressive treatment of SBP to <120 mm Hg could also reduce diastolic BP (DBP) to ≤70 or <60 mm Hg. Such lowering of DBP could reduce coronary blood flow, particularly in high-risk patients with preexisting coronary artery disease (CAD), and hypertension with or without left ventricular hypertrophy (LVH) and cause myocardial ischemia, MI, or CV death due to the J-curve effect. [3] [4] [5] In a recent paper I wrote regarding the impact of SPRINT on the future treatment of hypertension, I alluded to the possibility of adverse CV events from the aggressive control of BP due to the J-curve effect from the low DBP. 6 This prediction is supported by two recent publications 7, 8 reporting on the myocardial damage from the J-curve effect due to low DBP by measuring serial blood levels of high-sensitivity cardiac troponin T (hs-cTnT). This commentary addresses these two publications as well as other recent studies questioning the long-term safety of aggressive SBP and DBP control.
| CONTROVERSIES REGARDING THE AGGRESSIVE CONTROL OF BP
SPRINT is a unique and provocative study showing CV benefits of aggressive SBP control to <120 mm Hg in older patients with hypertension including those ≥75 years and older. However, these benefits were associated with serious adverse events of hypotension, syncope, electrolyte abnormalities, acute kidney injury, or acute renal failure in 4.7% in the intensive care group vs 2.5% in the standard care group (P<.001). The CV and stroke benefits of SPRINT have been reported elsewhere and by other large studies and reviews with less intensive BP controls and fewer adverse effects.
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The findings from these studies are summarized in 13 from a large retrospective study of hypertensive patients.
In this study, patients with a calculated SBP nadir of 137 mm Hg had the lowest incidence of CV mortality and end-stage renal disease.
Further increase or decrease of SBP from this level was associated with a higher incidence of adverse events. In addition, from a large review and meta-analysis, Xie and colleagues, 15 reported that reduc- <140 mm Hg had a lower incidence of CV events, coronary heart disease (CHD), and stroke than patients with an SBP ≥140 mm Hg.
| MECHANISM OF CV EVENTS WITH LOW DBP: THE J-CURVE EFFECT
The J-curve effect demonstrates a relationship between a range of BPs, mostly DBPs, and the incidence of CV complications which are the lowest when the DBP reaches a lowest point (nadir), after which any further increase or decrease of DBP is associated with a higher incidence of adverse CV events, including myocardial ischemia, chest pain, MI, and even death. The J-curve phenomenon seen with low DBP is due to the fact that coronary perfusion occurs during the diastolic phase of the cardiac cycle. Because the extraction of oxygen by the myocardium is complete, any further decrease in DBP, and, consequently, coronary blood flow, will result in myocardial ischemia despite the fact that the myocardium is protected through its autoregulatory mechanism from coronary pressures down to 45 mm Hg. 3 The presence of CAD and hypertension with or without LVH will shift the coronary autoregulation pressure upwards. The analysis of data has shown a J-curve effect of SBP ≥140 mm Hg and DBP ≥80 mm Hg and SBP <120 mm Hg and DBP <70 mm Hg, respectively. These BP levels were associated with a higher incidence of the primary composite outcome of CV death, MI, or stroke. 
| DISCUSSION
The results of the SPRINT study are impressive and provocative and deserve closer scrutiny. Achieving intensive SBP reductions will inevitably lead to lower DBP, which may result in myocardial damage long term through the J-curve effect. 7 For example, in a secondary analysis of SPRINT by Williamson and colleagues 2 of elderly participants (≥75 years), DBP fell from a mean baseline of 71.5 mm Hg to 62 mm Hg from the intensive treatment of SBP. This is of potential concern due to the J-curve effect of low DBP and CAD events.
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In their recent study, McEvoy and colleagues 7 present strong evidence that low DBP is associated with increased levels of hs-cTnT, an index of structural heart damage. Although the SPRINT study did not
show evidence for a J-curve effect, subclinical cardiac damage cannot be excluded. If the study was not stopped prematurely, adverse cardiac effects could have been demonstrated. Other large studies and reviews have shown that similar benefits could be obtained with similar or higher SBPs and DBPs. [9] [10] [11] [12] [13] [14] However, it should be recognized that the method used to measure BP in SPRINT was by an automatic device in the absence of a doctor or nurse to avoid the white-coat effect. Consequently, the BPs in SPRINT would likely be higher than those reported. Additionally, the results of SPRINT cannot be com- This analysis demonstrates that SBP lowering to ≤120 mm Hg would substantially increase the percentage of US adults who would benefit from SBP reduction. 28 This would result in significant increases in both the number of patients requiring treatment and the costs of care, since most SPRINT patients were taking an average of three medications.
| CONCLUSIONS
The SPRINT study demonstrating CV benefits in nondiabetic patients with hypertension is a landmark finding, and, although not definitive, Adjustments similar as in Table 2 . CHD, coronary heart disease; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio. and costs of care and will prevent the incidence of CV events from a possible J-curve effect from very low DBPs.
